AR-231,453
AR-231,453 is a drug that acts as a potent and selective agonist for the G protein-coupled receptor GPR119, which is mainly expressed in the pancreas and gastrointestinal tract. It is being researched for potential use in the treatment of diabetes.
Mechanism of action[edit | edit source]
AR-231,453 works by activating the GPR119 receptor. This receptor is found in the pancreas and gastrointestinal tract, where it plays a role in regulating glucose metabolism. When AR-231,453 binds to this receptor, it stimulates the release of insulin and glucagon-like peptide-1 (GLP-1), both of which help to control blood sugar levels.
Potential therapeutic uses[edit | edit source]
The main potential use for AR-231,453 is in the treatment of diabetes. By stimulating the release of insulin and GLP-1, it could help to improve blood sugar control in people with this condition. However, more research is needed to confirm its effectiveness and safety.
Research[edit | edit source]
AR-231,453 is currently in the early stages of research. Initial studies have shown promising results, but further trials are needed to fully understand its potential benefits and risks.
See also[edit | edit source]
AR-231,453 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD